Reset

Advanced Filters
Thursday

This preconference session reviews pharmacologic management of prevalent and benign urologic conditions including urinary tract infections, OAB/urge incontinence, prostatic enlargement, urinary retention/ incomplete bladder emptying, nocturia, painful bladder syndrome/interstitial cystitis, erectile dysfunction, and hypogonadism. A review the newest targeted therapies used for managing advanced stage urologic cancers is presented. Emphasis is placed on the role of Advanced Practice Provider and expert clinician related to pharmacologic management of these prevalent and clinically relevant urologic conditions.

Continuing Education Instructions and Disclosure Information:

Contact hours available until 10/31/23.

Requirements for Successful Completion:

Complete the learning activity in its entirety and complete the online nursing continuing professional development evaluation. You will be able to print your NCPD certificate at any time after you complete the evaluation.

Faculty, Planners, and Speakers Conflict of Interest Disclosure:

Planning Committee Disclosures:

There are no Planning Committee disclosures to declare.

Speakers Conflict of Interest Disclosure:
Mikel Gray, PhD, FNP, PNP, CUNP, CCCN, FAANP, FAAN – Consultant, Laborie Medical

Commercial Support and Sponsorship:
No commercial support or sponsorship declared.

Accreditation Statement:
The Society of Urologic Nurses and Associates (SUNA) is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

SUNA accreditation is reciprocal in the states and specialty organizations that recognize the ANCC-COA accreditation process. SUNA is also an approved provider of continuing nursing education by the California Board of Registered Nursing, Provider Number CEP 5556. Accreditation and approved provider status of NCPD does not imply ANCC-COA approval or endorsement of any product, advertising, or educational content. SUNA urges all participants to be aware of the CE requirements for re-licensure in the states in which they hold a license.

Learning Outcome:
After completing this education activity, the learner will be able to describe options for pharmacologic management of prevalent urologic conditions.


05:45pm - 06:45pm EDT - October 29, 2021

Friday

Overview of recent treatment advances utilizing checkpoint inhibitor immunotherapy in urothelial carcinoma, renal cell carcinoma, and prostate cancer.

Continuing Education Instructions and Disclosure Information:

Contact hours available until 10/31/23.

Requirements for Successful Completion:

Complete the learning activity in its entirety and complete the online nursing continuing professional development evaluation. You will be able to print your NCPD certificate at any time after you complete the evaluation.

Faculty, Planners, and Speakers Conflict of Interest Disclosure:

Planning Committee Disclosures:

There are no Planning Committee disclosures to declare.

Speakers Conflict of Interest Disclosure:
There are no speaker disclosures to declare.

Commercial Support and Sponsorship:
No commercial support or sponsorship declared.

Accreditation Statement:
The Society of Urologic Nurses and Associates (SUNA) is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

SUNA accreditation is reciprocal in the states and specialty organizations that recognize the ANCC-COA accreditation process. SUNA is also an approved provider of continuing nursing education by the California Board of Registered Nursing, Provider Number CEP 5556. Accreditation and approved provider status of NCPD does not imply ANCC-COA approval or endorsement of any product, advertising, or educational content. SUNA urges all participants to be aware of the CE requirements for re-licensure in the states in which they hold a license.

Learning Outcome:
After completing this education activity, the learner will be knowledgeable about the basic mechanism of action of checkpoint inhibitor immunotherapy to treat genitourinary malignancies.


03:35pm - 04:35pm EDT - October 30, 2021

Saturday

A review of the current AUA and NCCN guidelines for kidney cancer and how to apply these principles to clinical practice are presented in this session.

Continuing Education Instructions and Disclosure Information:

Contact hours available until 10/31/23.

Requirements for Successful Completion:

Complete the learning activity in its entirety and complete the online nursing continuing professional development evaluation. You will be able to print your NCPD certificate at any time after you complete the evaluation.

Faculty, Planners, and Speakers Conflict of Interest Disclosure:

Planning Committee Disclosures:

There are no Planning Committee disclosures to declare.

Speakers Conflict of Interest Disclosure:
There are no speaker disclosures to declare.

Commercial Support and Sponsorship:

No commercial support or sponsorship declared.

Accreditation Statement:
The Society of Urologic Nurses and Associates (SUNA) is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

SUNA accreditation is reciprocal in the states and specialty organizations that recognize the ANCC-COA accreditation process. SUNA is also an approved provider of continuing nursing education by the California Board of Registered Nursing, Provider Number CEP 5556. Accreditation and approved provider status of NCPD does not imply ANCC-COA approval or endorsement of any product, advertising, or educational content. SUNA urges all participants to be aware of the CE requirements for re-licensure in the states in which they hold a license.

Learning Outcome:
After completing this education activity, the learner will be able to confidently work up and counsel patients with a new renal mass.